Serum Protein Changes and Acute‐Phase Response in Patients Receiving Doxorubicin–Cyclophosphamide Chemotherapy in Ethiopia: A Prospective Cohort Study
Cancer Reports · 2026-11 · 9 (11)
DOI: 10.1002/cnr2.70776 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Reports, online erschienen am 20.11.2026. Verfasst von Tamrat Nida und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with breast cancer in low and middle income countries (LMICs) receiving doxorubicin–cyclophosphamide (AC) chemotherapy face heightened toxicity risks due to limited supportive care infrastructure.
Aims
This prospective study characterized changes in serum total protein, albumin, and high sensitivity‐C‐reactive protein (Hs‐CRP) during AC chemotherapy in Ethiopian women with breast cancer and described these changes by age, menopausal status, body mass index (BMI), and disease stage.
Methods
In this single‐center cohort study at Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, 45 adult women with histologically confirmed invasive breast carcinoma scheduled for neoadjuvant or adjuvant AC chemotherapy were enrolled. Serum total protein, albumin, and Hs‐CRP were measured at baseline and 21–28 days after Day 1 of the fourth AC cycle. Analyses were complete‐case. Pre‐to‐post changes were evaluated by paired t ‐tests and Wilcoxon signed‐rank tests. Time × subgroup interactions were assessed by repeated measures ANOVA, with Hs‐CRP natural‐log transformed for the interaction tests. Bonferroni correction was applied across six interaction tests. Subgroup analyses were unadjusted and exploratory; multivariable regression and sensitivity analyses were not performed.
Results
Forty‐two patients (93.3%) completed both assessments (mean age 44.8 ± 11.9 years; 52.4% premenopausal; 64.3% Stage III; no Stage IV). After four AC cycles, mean serum total protein declined from 7.3 ± 0.6 to 7.0 ± 0.7 g/dL (−4.1%; p = 0.020) and albumin from 4.1 ± 0.4 to 3.8 ± 0.5 g/dL (−7.3%; p < 0.001), while median Hs‐CRP rose from 3.2 (IQR: 1.8–4.5) to 6.1 (IQR: 3.9–8.4) mg/L (+90.6% in medians; median paired difference + 2.6 mg/L, bootstrapped 95% CI 1.8–3.4; p < 0.001). Hypoalbuminemia prevalence increased from 7.1% (3/42) to 38.1% (16/42). The proportion with Hs‐CRP > 3.0 mg/L increased from 52.4% (22/42) to 83.3% (35/42). Patients aged ≥ 56 years showed the steepest albumin decline (−12.8%; interaction p = 0.006, Bonferroni adjusted 0.036). Hs‐CRP rose numerically more in patients aged ≥ 56 years, in postmenopausal women, and in Stage III disease, but none of these interactions, nor the albumin interactions by menopausal status and stage, remained statistically significant after Bonferroni correction, and they are exploratory. Delta albumin and delta‐Hs‐CRP were inversely correlated (Spearman's r = −0.62; p < 0.001).
Conclusions
In Ethiopian women receiving four cycles of AC chemotherapy, serum total protein and albumin fell and Hs‐CRP rose, with a larger albumin decline in women aged ≥ 56 years; numerical differences by menopausal status and stage were not statistically significant after correction. The pattern is consistent with an acute‐phase response; hepatic synthetic function was not assessed, and other contributors such as infection, hemodilution and reduced intake could not be excluded. These descriptive findings are hypothesis generating, and larger studies with clinical outcomes are needed before albumin and Hs‐CRP are used to guide supportive care.
Zitieren
APA
Nida, T., & Bedada, A. T. (2026). Serum Protein Changes and Acute‐Phase Response in Patients Receiving Doxorubicin–Cyclophosphamide Chemotherapy in Ethiopia: A Prospective Cohort Study. Cancer Reports, 9(11). https://doi.org/10.1002/cnr2.70776
Vancouver
Nida T, Bedada AT. Serum Protein Changes and Acute‐Phase Response in Patients Receiving Doxorubicin–Cyclophosphamide Chemotherapy in Ethiopia: A Prospective Cohort Study. Cancer Reports. 2026;9(11). doi:10.1002/cnr2.70776
BibTeX
@article{Nida2026,
author = {Nida, Tamrat and Bedada, Abdisa Tufa},
title = {Serum Protein Changes and Acute‐Phase Response in Patients Receiving Doxorubicin–Cyclophosphamide Chemotherapy in Ethiopia: A Prospective Cohort Study},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/cnr2.70776}
}
EUVIMED